According to analysis by Future Market Insights (FMI), the global axillary hyperhidrosis treatment market was valued at USD 1.6 billion in 2022 and is expected to reach approximately USD 3.3 billion by 2033.
This anticipated growth reflects an increasing awareness and diagnosis of axillary hyperhidrosis, a condition characterized by excessive sweating in the underarm area. As more individuals seek effective treatment options to manage their symptoms, the demand for innovative therapies and interventions is expected to rise.
Factors contributing to this market expansion include advancements in treatment technologies, such as minimally invasive procedures and new pharmaceutical options, which enhance patient outcomes and satisfaction. As awareness of hyperhidrosis grows, along with the societal emphasis on personal comfort and hygiene, the market for axillary hyperhidrosis treatments is poised for significant growth in the coming years.
Healthcare providers and pharmaceutical companies focusing on this area will find substantial opportunities to develop and offer effective solutions that address the needs of individuals affected by this challenging condition.
Anti-sweat injections are nowadays considered to be the best option for treating axillary hyperhidrosis as these don’t require any incisions.
Doctors are now employing Botox as a successful alternative to treat hyperhidrosis for individuals who want long-lasting results or for whom conventional antiperspirants are ineffective. The FDA has licensed Botox for the treatment of axillary hyperhidrosis in individuals who frequently perspire.
- The less invasive aspect of Botox injections, the less pain when administered into the armpits, and the generally safe technique are factors that have driven people to select Botox treatment for long-term results. Further growth is anticipated for this trend, which will help the market flourish.
Medicated wipes and gels are also effective substitutes. These products contain active ingredients such as aluminum chloride or aluminum zirconium tetrachlorohydrex glycine, which work by blocking sweat ducts and reducing the amount of sweat produced. One advantage of medicated wipes and gels is that they are non-invasive and do not require any medical procedures. However, another advantage is that they can be more effective than other traditional treatment options. Medicated wipes and gels contain higher concentrations of active ingredients, which can provide longer-lasting and more reliable results.
What are the Key Opportunities in the Axillary Hyperhidrosis Treatment Market?
There is a lack of awareness regarding axillary hyperhidrosis, which is excessive sweating in the armpits Many people who suffer from this condition may not realize that it is a medical condition that can be treated. They may be embarrassed to talk about it, or believe it is just a normal reaction of their body to heat or stress.
As a result, many people with axillary hyperhidrosis do not seek treatment, which can lead to social isolation, anxiety, and low self-esteem. Secondly, healthcare providers may not recognize the condition or may not know how to effectively treat it.
Healthcare professionals are also experimenting with various combination therapies/treatments and seeing positive results in their patients, especially with oral medications. Oral medications are generally not a viable, long-term, sole option due to their side effects. Instead, other treatments can be combined with them to achieve the best results, and new formulations can make them easier for more patients.
- Botulinum toxin injections and oral medications are an example of combined treatment for hyperhidrosis. Botulinum toxin injections are a common treatment for hyperhidrosis, but they may not be effective for axillary hyperhidrosis or in all patients. Oral medications such as anticholinergics or beta blockers may be used in combination with botulinum toxin injections to reduce sweating.
Increased testing of combination therapies in patients will pave the way for new drug discoveries and treatment options, ultimately leading to the introduction of new products into the market.
Competitive Landscape
Key players in the market are focused on increase their product portfolio to strengthen their position in the axillary hyperhidrosis treatment market, and also to expand their footprint in emerging markets. The key strategy adopted by manufacturers to gain competitive edge in the market are the pricing strategies, market strategies, technological advancements, regulatory compliance and acquisition & distribution agreement of other companies to expand their business.
For instance
- In April 2021, Journey Medical Corporation and Dermira, Inc subsidiary of Eli Lilly and Company, entered into an agreement to acquire QBREXZA®.
- In May 2020, AbbVie announced that it had completed the acquisition of Allergan Plc after obtaining all regulatory approvals required under the transaction agreement and obtaining the approval of the Irish High Court.
Key Companies Profiled
Allergan plc. (AbbVie); Journey Medical Corporation (Dermira, Inc.); Riemann A/S (Orkla); SweatBlock; Certain Dri; miraDry, Inc. (Sientra); STRATUS PHARMACEUTICALS INC; Duradry; Persn & Covey; GlaxoSmithKline Plc.; Carpe; SweatStop® International; CORAD Healthcare; ZeroSweat
Key Segments Covered in Axillary Hyperhidrosis Treatment Industry Research
By Treatment:
- Drug Therapy
- Antiperspirants (Both OTC & Rx)
- Antiperspirants Spray
- Antiperspirants Roll-On
- Antiperspirants Wipes
- Antiperspirants Lotion & Gel
- Antihypertensive Drugs
- Anticholinergic Agents
- Alpha-Adrenergic Agonists
- Antiperspirants (Both OTC & Rx)
- Botulinum Toxins
- Medicated Wipes
- Microwave Therapy
By Distribution Channel:
- Hospitals
- General Physician’s Clinics
- Retail Pharmacy Chains
- Drug Stores
- Online Sales
- Manufacturer websites
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
